Core Viewpoint - COSCIENS Biopharma Inc. has reported its financial and operational results for the fourth quarter and full year of 2025, highlighting significant restructuring efforts and strategic decisions aimed at improving financial stability and shareholder value [1][5]. Corporate Update - Following the reconstitution of the Board on May 30, 2025, the Company has initiated a comprehensive restructuring plan to streamline operations and enhance efficiency, resulting in a reduced burn rate and alignment with market conditions [2]. - The Company has ceased funding its German subsidiaries, leading to an application for insolvency proceedings, which is expected to generate approximately $1.9 million in annualized cost savings [3]. - The Company plans to further reduce administrative costs by terminating or suspending public reporting obligations under the Securities Exchange Act, while continuing to meet Canadian securities laws [4]. Financial Summary - As of December 31, 2025, the Company had $7.3 million in cash and cash equivalents [6]. - The consolidated net loss for Q4 2025 was $2.2 million, a decrease from $6.7 million in Q4 2024, primarily due to reductions in impairment expenses, R&D costs, income tax expense, and SG&A expenses [6][12]. - For FY 2025, the consolidated net loss was $10.4 million, down from $15.3 million in FY 2024, attributed to decreases in impairment and R&D costs [6][12]. - Total revenue for Q4 2025 was $1.8 million, down from $3.3 million in Q4 2024, mainly due to declines in pharmaceutical revenue and sales of active ingredients [7][12]. - Total revenue for FY 2025 was $7.5 million, compared to $9.6 million in FY 2024, reflecting a decrease primarily in active ingredient sales and pharmaceutical revenue [12]. Future Outlook - The Company is committed to pursuing additional cost-savings, achieving profitability, and exploring opportunities to enhance shareholder value through organic growth and strategic transactions [5].

Core Viewpoint - COSCIENS Biopharma Inc. has decided to cease funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, leading to an anticipated structured insolvency process for these entities [1][2]. Company Strategy - The company has historically focused on developing its pharmaceutical assets, particularly Macrilen (macimorelin), through its German subsidiaries, which have operated at a loss [2]. - The long-term viability of the biopharmaceutical business has depended on expanding the market for Macrilen, especially through obtaining FDA approval for a pediatric indication in the U.S. [2]. - Following disappointing results from Macrilen's Phase 3 DETECT trial and a subsequent meeting with the FDA, the company is exploring various strategic options, including potential sales of the product or subsidiaries and additional licensing opportunities [2]. Financial Implications - The expected insolvency process will result in the company surrendering its rights to Macrilen and significantly reducing ongoing operating expenses [3]. - The decision to stop funding the German subsidiaries is viewed as a necessary step towards achieving profitability for the company [3]. Future Focus - Moving forward, the company will concentrate on maximizing profitability from its active ingredients business and evaluating other opportunities [3][4].

Core Viewpoint - COSCIENS Biopharma Inc. has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited for the commercialization of Macrilen in specific Asian markets, aiming to address the unmet need for growth hormone deficiency diagnostics [1][2][3]. Company Overview - COSCIENS Biopharma Inc. focuses on pharmaceutical therapies, diagnostic products, and natural ingredient solutions, with a diverse portfolio that includes the development of natural, plant-based active ingredients [5]. - The company's lead product, Macrilen (macimorelin), is the first and only FDA and EMA approved oral test for diagnosing Adult Growth Hormone Deficiency (AGHD) [6]. Distribution Agreement Details - The agreement with Wuzhou covers the registration, importation, and commercialization of Macrilen in Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan [2]. - The partnership is structured for an initial ten-year term, with Wuzhou committing to a minimum initial order of approximately €800,000 [2]. Strategic Importance - The collaboration is expected to leverage the "Hong Kong and Macao Medicine and Equipment Connect" policy, facilitating expedited market access in the Guangdong-Hong Kong-Macao Greater Bay Area [2]. - The agreement is seen as a key step in COSCIENS' strategy to unlock the global potential of Macrilen and establish sustainable revenue streams [3]. Market Potential - The partnership aims to meet the significant demand for a convenient, oral diagnostic option for patients suspected of AGHD in the dynamic Asian markets [3]. - Wuzhou's expertise in regulatory processes and hospital networks is expected to enhance the approval pathways for Macrilen in the targeted regions [4].